Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 ~2x weekly·8 episodes·Last published 4d ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 12 epsHost
Recent guests
No guests detected in recent episodes.
Recent episodes
An Oral GLP-1 That Works: ATTAIN-2 and the 2026 ADA Standards | This Week in Diabetes & Endocrinology
Jun 20, 2026
9m 32s
The Week in Endocrinology Oral Ozempic & Emerging Therapies
May 12, 2026
5m 01s
Week in Diabetes & Endocrinology (May 4, 2026): AID in Pregnancy, Tirzepatide ICERs, AACE Signals, Dapagliflozin & Anemia, Hypoglycemia Models, Oat Diet Trial
May 5, 2026
15m 56s
HORMONE INSIGHT -- THE WEEK IN DIABETES & ENDOCRINOLOGY -- Episode 004 | April 24, 2026
Apr 24, 2026
13m 32s
The Week in Diabetes and Endocrinology April 17, 2026
Apr 22, 2026
17m 41s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/20/26 |  An Oral GLP-1 That Works: ATTAIN-2 and the 2026 ADA Standards | This Week in Diabetes & Endocrinology | This week on This Week in Diabetes & Endocrinology, from Hormone Insight: thefirst large phase 3 trial of an oral GLP-1, orforglipron, in adults with type 2diabetes and obesity (ATTAIN-2, Lancet). The headline is not the size of theweight loss. It is the word oral.Also this week:- A 112,000-patient ACP network meta-analysis that keeps semaglutide and tirzepatide on top for both weight loss and cardiovascular outcomes- A provocative real-world comparison of bariatric surgery versus semaglutide in fatty liver disease- The 2026 ADA Standards of Care, which make cardiovascular and kidney protection a co-primary goal alongside A1C- A Hormone Classic revisit of UKPDS that explains why that shift had to happenOne question runs through all of it: does this change Monday clinic?Chapters00:00 Cold open00:42 This week01:13 Trial of the Week: orforglipron (ATTAIN-2)04:29 Quick Hit: ACP weight-loss drug meta-analysis05:21 Quick Hit: surgery vs semaglutide (MASLD)06:21 Guideline & FDA Watch: 2026 ADA Standards07:27 Hormone Classics: UKPDS08:26 The Bottom Line08:57 Sign-offReferences and written summary: hormoneinsight.com/[slug]For healthcare professionals. Educational, not individual medical advice.Subscribe for a new episode every Saturday.#diabetes #endocrinology #GLP1 #obesity #ADA2026 | 9m 32s | ||||||
| 5/12/26 | The Week in Endocrinology Oral Ozempic & Emerging Therapies✨ | Oral Ozempicsemaglutide+4 | — | Oral Ozempicsemaglutide+2 | Canada | Oral Ozempicsemaglutide+5 | — | 5m 01s | |
| 5/5/26 | Week in Diabetes & Endocrinology (May 4, 2026): AID in Pregnancy, Tirzepatide ICERs, AACE Signals, Dapagliflozin & Anemia, Hypoglycemia Models, Oat Diet Trial✨ | diabetes updatesendocrinology+5 | — | Tandem Control-IQ Plustirzepatide+5 | CKD | diabetesendocrinology+7 | — | 15m 56s | |
| 4/24/26 | HORMONE INSIGHT -- THE WEEK IN DIABETES & ENDOCRINOLOGY -- Episode 004 | April 24, 2026✨ | DiabetesEndocrinology+4 | — | Tzield (Teplizumab)Orforglipron+7 | — | TzieldTeplizumab+6 | — | 13m 32s | |
| 4/22/26 | The Week in Diabetes and Endocrinology April 17, 2026✨ | DiabetesEndocrinology+4 | — | EnlicitideSemaglutide+3 | — | diabetesendocrinology+6 | — | 17m 41s | |
| 4/9/26 | Episode 002: LDL Under 55 Wins Big, Medicare Covers GLP-1, and Second Weekly Insulin Emerges -- The Week in Diabetes & Endocrinology (April 10, 2026)✨ | diabetesendocrinology+4 | — | Hormone InsightFWA+6 | — | LDL Under 55Medicare GLP-1+5 | — | 16m 45s | |
| 4/5/26 | The Week in Diabetes and Endocrinology -- April 3, 2026✨ | DiabetesEndocrinology+4 | — | OrforglipronSemaglutide+4 | — | DiabetesEndocrinology+5 | — | 23m 36s | |
| 6/14/25 | Early Onset Type 2 Diabetes and Tirzepatide (SURPASS Post Hoc Analysis)✨ | Type 2 DiabetesTirzepatide+3 | — | TirzepatideDiabetes Care | — | Type 2 DiabetesTirzepatide+3 | — | 1m 14s | |
| 1/4/25 | Exploring Semaglutide: Therapy for Obesity and Heart Failure✨ | semaglutideobesity+3 | — | semaglutideNew England Journal of Medicine | 2024 | semaglutideobesity+3 | — | 0m 51s | |
| 12/19/24 | Semaglutide vs Canagliflozin for Type 2 Diabetes✨ | diabetes treatmentsemaglutide+4 | — | semaglutidecanagliflozin+2 | Type 2 Diabetes | semaglutidecanagliflozin+4 | — | 1m 04s | |
| 11/22/24 |  Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients✨ | heart failuretirzepatide+4 | — | tirzepatideNew England Journal of Medicine | obesity | tirzepatideheart failure+5 | — | 3m 38s | |
| 11/18/24 | Intensive Blood-Pressure Control in Patients with Type 2 Diabetes✨ | blood pressure controltype 2 diabetes+3 | — | New England Journal of Medicine | — | intensive blood-pressure controltype 2 diabetes+4 | — | 3m 36s | |
| 10/20/24 | Phase 2 trial on Semaglutide✨ | semaglutidetype 2 diabetes+5 | — | semaglutideGLP-1 analog+3 | — | semaglutidetype 2 diabetes+5 | — | 3m 39s | |
Showing 13 of 13
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.